Skip to main content
Premium Trial:

Request an Annual Quote

Essen BioScience to Screen Nycomed Drug Candidates

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Essen BioScience today said that it will provide ion channel screening services for Swiss drug firm Nycomed.

Ann Arbor, Mich.-based Essen said that the firms will collaborate on screening, optimizing, and developing modulators of voltage-gate ion channels for potential use as pain therapeutics. Essen said that it will contribute its expertise in ion channel drug discovery, planar array electrophysiology, and in vitro profiling.

Financial terms of the alliance were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.